Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy

Fig. 7

Akti-treated CD19CAR TCM + and CD19CAR naïve/memory T cells exhibit greater anti-tumor efficacy in vivo. TCM and naïve/memory T cells from healthy donors were isolated and activated with CD3/CD28 Dynabeads and transduced the next day with CD19R (EQ):CD28:ζ/EGFRt lentivirus at an MOI of 3. The cultures were supplemented with 50 U/mL rhIL-2 and Akt inhibitor every 48 h for 21 days. Transduced CD19CAR T cells without Akt inhibitor treatment were used as control. Non-transduced mock T cells were used as another type of control. Acute lymphoid leukemic 0.5 × 106 SupB15 cells engineered with GFPffluc were inoculated into NSG mice (N = 5 mice per group) intravenously (i.v) on day -5. After confirmation of the tumor engraftment, 1 × 106 expanded CD19CAR+ T cells were adoptively transferred into tumor-bearing mice intravenously. Tumor signals were monitored by Biophotonic tumor imaging and the bioluminescence signal was measured as total photon flux normalized for exposure time and surface area and expressed in units of photons (p) per second per cm2 per steradian (sr). a Percentages of CD8 and CAR positive cells in the input CD19CAR TCM population are presented. b Tumor signals at different time points are presented. c Percentages of CD8 and CAR positive cells in the input CD19CAR naïve/memory population are presented. d Tumor signals at different time points are presented

Back to article page